Examining Cannabis Stocks Earnings: CGC, CRON, MSOS

<p>Alan Brochstein, Managing Partner at New Cannabis Ventures and Principal at 420 Investor, examines cannabis stocks. He discusses what investors have learned from Canopy Growth’s (CGC) earnings. He talks about Cronos’ (CRON) 2Q revenue which came in at $15.60M versus an estimated $18.08M. He also mentions AdvisorShares Trust Pure US Cannabis ETF (MSOS). Tune in to find out more.</p>